REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 7th, 2009 • SignPath Pharma, Inc. • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made effective as of December __, 2008, by and among SignPath Pharma, Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT To Purchase ______ Shares of Common Stock of SIGNPATH PHARMA INC.Warrant Agreement • April 7th, 2009 • SignPath Pharma, Inc. • Delaware
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) CERTIFIES that, for value received, _____________ (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance of this Warrant (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York time) on the five-year anniversary of the Effective Date (as defined below) (the “Termination Date”) but not thereafter, to subscribe for and purchase from SignPath Pharma Inc., a Delaware corporation (the “Company”), up to _____ shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price per share of Common Stock (the “Exercise Price”) under this Warrant shall be $1.27 subject to adjustment hereunder.
SUBSCRIPTION AGREEMENTSubscription Agreement • April 7th, 2009 • SignPath Pharma, Inc. • New York
This Subscription Agreement (this “Agreement”), dated as of December 12, 2008, by and among SignPath Pharma, Inc., a Delaware corporation (the “Company”), and each subscriber identified on the signature page hereto (each a “Subscriber” and collectively the “Subscribers”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 7th, 2009 • SignPath Pharma, Inc. • New York
AGREEMENT made as of the 1st day of July, 2007 by and between Lawrence Helson, MD (hereinafter referred to as the “Employee”) and SignPath Pharma, Inc., a Delaware Corporation.
Agreement for the Manufacturing of a Liposomal FormulationManufacturing Agreement • April 7th, 2009 • SignPath Pharma, Inc.
Contractor is obliged to maintain the Contractual Intellectual Property Rights during the term of this Agreement at his own costs.
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY SIGN PATH PHARMA JHU Agreement #A11537Exclusive License Agreement • April 7th, 2009 • SignPath Pharma, Inc. • Delaware
THIS LICENSE AGREEMENT (the “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”) and Sign Path Pharma, Inc., a Delaware corporation having an address at 45 Broadway, New York, New York 10006 (“Company”), with respect to the following:
SERVICE AGREEMENTService Agreement • April 7th, 2009 • SignPath Pharma, Inc. • Delaware
THIS AGREEMENT (“Agreement”), effective January 30, 2008 (the "Effective Date"), is by and between Sign Path Pharmaceuticals, Inc., a company incorporated in the State of Delaware and having its office at Office at 45 Broadway 2nd Floor New York, NY 10006, USA (“CLIENT”) and BROOKWOOD PHARMACEUTICALS, INC having a principal place of business at 756 Tom Martin Drive, Birmingham, Alabama 35211 ("BROOKWOOD").
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • April 7th, 2009 • SignPath Pharma, Inc. • Texas
This thirty (30) page AGREEMENT ("AGREEMENT") is made on this 21st day of February, 2007, by and between THE BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a component institution of SYSTEM, and SIGNPATH PHARMACEUTICALS, INC., a Delaware corporation having a principal place of business located at 45 Broadway, 2nd Floor, New York, New York 10006 ("LICENSEE").
